An interesting paper, titled Ancient Indigenous Deoxyribonucleic Acid (DNA) and Intellectual Property Rights, was presented at the recent IV International Graduate Legal Research Conference (IGLRC) hosted by King's College London School of Law and Graduate School by Fiona Batt of Bristol University, raised a number of questions and launched a fascinating and attractive topic.
Ms Batt mentioned that, because of the developments in science, body parts and genetic material are becoming 'property' which is protected and controlled by IP rights. She started from the obvious, patent, and then explored traditional knowledge and even trade secrets. But at the end, the question is: who is the owner of ancient indigenous DNA when extracted?
While this appears to be somehow clear, the main challenge is: who would be the owner to prevent such extraction? She brought into attention the American and Western cultures, points out Venezuelan lawyer Patricia Covarrubia, who also presented at the meeting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze